Actively Recruiting
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
Led by Yuhan Corporation · Updated on 2025-11-21
86
Participants Needed
1
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized, double-blind, first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of YH35995
CONDITIONS
Official Title
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male between the ages of 19 and 45 at the time of providing written consent
- Weigh at least 50 kg at screening
- Have a body mass index (BMI) of at least 18.0 kg/m2 and less than 30 kg/m2
- Fully informed about and understand the study
- Voluntarily agree to participate and comply with study guidelines during the study
You will not qualify if you...
- Participation in a bioequivalence trial or any other clinical trial within 6 months prior to the first dose (within 1 month for dietary supplement trials)
- Clinically significant abnormal results not covered by other criteria, as determined by the investigator
- Unwilling or unable to comply with the participant guidelines described in the protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHA Bundang Medical Center
Seongnam, Bundang-gu, South Korea, 13496
Actively Recruiting
Research Team
J
Jeeyeon Kim
CONTACT
S
Sungjae Lee
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here